Seattle startup Adaptive Biotechnologies that makes tools for cancer diagnosis and prognosis is seeking $20 million, according to a regulatory filing. The company has already raised $5 million. A filing from 2012 shows that Adaptive was seeking more than $5 million and ended up raising $2.65 million. Founded in 2009, Adaptive focuses on profiling the immune system. Its flagship product is the immunoSEQ, which the company describes as a "suite of next generation immune sequencing assays that allow researchers to view and analyze the T and B cells of the adaptive immune system with unprecedented depth and specificity."